Pyrido[3,2-d]pyrimidine Derivatives for Selective TLR8 Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for novel, potent, and selective modulators of Toll-like Receptor 8 (TLR8) with reduced potential for off-target liabilities to treat various diseases including viral infections and cancer, as existing modulators may have unwanted effects on other immune receptors.
Innovation Solution
Development of specific compounds and pharmaceutical compositions that selectively modulate TLR8, potentially combined with other therapeutic agents, to stimulate immune responses and treat conditions like hepatitis B, HIV, and cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing TLR8 modulators are used to stimulate immune responses, then therapeutic benefit is achieved, but off-target effects on other immune receptors occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (pyrido[3,2-d]pyrimidine core with particular substituent patterns at positions 4 and 6) that confer selective affinity for TLR8 over other TLRs. The molecular structure is locally optimized with specific functional groups and spatial arrangements that match TLR8 binding pockets, enabling selective interaction without activating other immune receptors.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types, positions, and configurations on the pyrido[3,2-d]pyrimidine core. By adjusting these chemical parameters, the compounds achieve optimal selectivity for TLR8 while maintaining potent agonist activity, thereby reducing off-target effects on other immune receptors.
2Reliability
If potent TLR8 agonists are developed to treat viral infections and cancer, then therapeutic efficacy is improved, but potential side effects from broad immune activation increase
Solution Approach 1:
The compounds are designed with specific local structural characteristics that enable selective TLR8 activation. The pyrido[3,2-d]pyrimidine core with defined substituent patterns creates a molecular configuration that preferentially binds TLR8, thereby activating immune responses through TLR8 specifically while avoiding broad activation of other immune pathways that could lead to unwanted side effects.
3Reliability
If novel TLR8 modulators are designed with high selectivity, then off-target liabilities are reduced, but development complexity and time increase
Solution Approach 1:
The patent applies segmentation by dividing the molecular design into distinct functional segments: a core pyrido[3,2-d]pyrimidine structure and separate substituent groups at positions 4 and 6. This modular approach allows systematic optimization of selectivity by independently designing and testing different substituent combinations, thereby managing structural complexity through organized segmentation rather than attempting to optimize the entire molecule simultaneously.
Data Source
AI summary
This application relates generally to toll like receptor modulator compounds as defined below and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.